60 years ago, respiratory syncytial virus (RSV) was identified in children admitted to hospital in Baltimore, MD, USA, with bronchiolitis or pneumonia. 1 Since that time, RSV has been established as a leading cause of acute lower respiratory illness (ALRI) in infants and children living in all regions of the world. [2] [3] [4] [5] As the widespread use of Haemophilus influenzae type b and pneumococcal conjugate vaccines decreases the burden of bacterial pneumonia in children, the proportional contribution of RSV to childhood ALRI will continue to increase. Substantial effort is being put into RSV disease prevention; more than 15 RSV vaccines and vaccine-like monoclonal antibodies (mAbs) are currently being assessed in clinical trials. 6 The burden of RSV disease in children-both in hospital and in the community-has been well described in many high-income settings. 7, 8 However, our understanding of the age-specific incidence of RSV disease and its contribution to paediatric mortality in low-income and middle-income countries (LMICs) has lagged behind. In 2010, Nair and colleagues 2 published an estimate of what the global RSV morbidity and mortality had been in children younger than 5 years during 2005; this study was an important contributor to our understanding of the global impact of RSV, but had limitations associated with non-uniform case definitions and a broad range for estimated mortality (66 000-199 000 deaths, with no point estimate possible). Moreover, this study was not able to provide RSV morbidity and mortality estimates by narrow age strata in the first year of life, which is important to plan future passive and active RSV immunisation strategies.
In The Lancet, Ting Shi and colleagues 9 present new global estimates of the incidence, hospital admission rates, and deaths for RSV-associated ALRI based on a literature review in all languages, including Chinese, an extensive search for unpublished data, and application of standardised case definitions. They estimate that in 2015, 33·1 million (uncertainty range [UR] 21·6-50·3) episodes of RSV-ALRI resulted in about 3·2 million (2·7-3·8) hospital admissions and 59 600 (48 000-74 500) in-hospital deaths in children younger than 5 years. In children younger than 6 months, they estimate that 1·4 million (1·2-1·7) hospital admissions, and 27 300 (20 700-36 200) in-hospital deaths were due to RSV-ALRI. And they estimate that overall RSV-ALRI mortality could be as high as 118 200 (94 600-149 400).
These data substantially increase the quality and quantity of information available to make RSV disease burden estimates, yet some remaining gaps limit their certainty and our ability to prioritise efforts to develop effective interventions. The most substantial data are available for overall RSV hospital admissions; less information is available for hospital admissions by age, especially in neonates, and for RSV illness and mortality in the community. The estimated deaths from RSV-associated ALRI of 118 200 (94 000-149 400) would constitute 8·2% of the estimated 1·438 million deaths classified as sepsis or pneumonia in 2015. 10 The uncertainty is probably greater than that reflected in the range given, which is based on the data used.
The proportion of RSV-associated ALRI and deaths that occur outside of hospitals in LMICs is unknown and likely to be high. Estimation of RSV-associated ALRI deaths, including those that occurred at home, is based only on data from sites in rural Bangladesh, urban slums in Argentina, and rural hamlets in Indonesia where the excess ALRI mortality during RSV season was used to calculate the ratio between community and in-hospital deaths in each site. The mean of these three ratios was used to inflate the estimated in-hospital deaths in LMICs to estimate the total RSV deaths, adjusted for the co-occurrence of influenza. The possible effect of several factors, including the variation by place and time in RSV infection rates, the limited information available to allow attribution of excess deaths to RSV versus influenza or other infections with overlapping seasonality, a risk relationship of RSV with pneumococcal infections, 11 and possible alterations of hospital admission rates or hospital case fatality rates in research sites, suggest that available data might limit our ability to accurately assess global RSV mortality. Additional studies of community-based RSV mortality are needed, with a particular focus on mortality in the first months of life and possible amelioration of mortality through introduction of pneumococcal conjugate vaccines.
What are the implications of this study for RSV prevention strategies? Contrary to data from many previous epidemiological studies, this study finds a substantial RSV disease burden in neonates, with estimates of 40 episodes per 1000 neonates per year (95% CI 2·5-635·7). These data, along with the substantial rate of disease in the 1-5 month age group, suggest the necessity of passive protection against RSV infection at birth, either through maternal immunisation or administration of a birth dose of an extended half-life mAb. 6 However, this study also finds a substantial RSV disease burden in older infants and young children: more than 80% of RSV-ALRI (about 27·5 of about 33 million cases) and more than half of all RSV in-hospital deaths (about 32 000 of about 60 000 deaths) are estimated to have occurred in infants older than 6 months of age, well beyond the reach of protection likely to be afforded by maternal immunisation. 12 These data suggest the importance of developing vaccines for active infant immunisation to provide durable protection against RSV disease. Finally, as this and previous studies have shown, 2,3,9 the overwhelming burden of RSV disease is in LMICs. The development of vaccines and mAbs for RSV disease prevention that are affordable and globally available must be a public health priority.
